Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Caffeine/naproxen sodium - Bayer

Next Previous
Drug Profile

Caffeine/naproxen sodium - Bayer

Alternative Names: BAY-2880376

Latest Information Update: 21 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Xanthines
  • Mechanism of Action Central nervous system stimulants; Cyclooxygenase inhibitors; Phosphoric diester hydrolase inhibitors; Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 29 Jan 2024 Bayer completes a phase III trial in Postoperative pain (In adolescents, In the elderly, In adults, In volunteers) in USA (PO) (NCT05485805)
  • 21 Sep 2022 Phase-III clinical trials in Postoperative pain (In adolescents, In the elderly, In adults, In volunteers) in USA (PO) (NCT05485805)
  • 08 Aug 2022 Caffeine/naproxen sodium is still in phase-II clinical development for Postoperative pain (In adolescents, In the elderly, In adults) in USA (PO) (NCT05485805)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top